It is estimated that 75% of women will experience an episode of vulvovaginal candidiasis (VVC) in their lifetimes, and with several OTC treatment options, incidence may be underreported.^1,2 Based on the results of the VANISH 303 (NCT03734991) and VANISH 306 (NCT03987620) studies, ibrexafungerp (Brexafemme) was recently FDA approved for VVC treatment. It is a new, first-in-class triterpenoid antifungal and the first new antifungal class since the echinocandins were approved in the early 2000s.